Salmon calcitonin combined with vitamin D3 in the treatment of hyperparathyroidism secondary to chronic renal insufficiency / 中国医师杂志

ABSTRACT

Objective:To explore the efficacy of salmon calcitonin combined with vitamin D3 in the treatment of chronic renal insufficiency and secondary hyperthyroidism and its effects on bone calcium metabolism.Methods:A total of 40 patients with chronic renal failure who underwent hemodialysis in our blood purification center from September 2017 to December 2017 were selected for the study and were divided into treatment group (20 cases) and control group (20 cases) according to the random number table method. Patients in control group were given conventional treatment + calcitriol orally, and patients in treatment group were given subcutaneous injection of salmon calcitonin on the basis of control group. The course of treatment in both groups was 12 weeks. The clinical efficacy and clinical symptoms improvement, serum calcium, serum phosphorus and parathyroid hormone (iPTH) as well as the adverse reactions were compared between the two groups. The Kidney Disease Targeted Areas (KDTA) and Visual Analogue Pain Score (VAS) were used to evaluate the patients' quality of life and bone pain.Results:The effective rate in treatment group was significantly higher than that in control group (95.00% vs 65.00%) ( P<0.05). The clinical symptoms of bone joint pain, muscle weakness and skin itching were significantly improved in the two groups, and the improvement was more significant in treatment group compared with that in control group ( P<0.05). The serum calcium levels in the two groups were significantly increased ( P<0.05), while the levels of serum phosphorus and iPTH were significantly decreased ( P<0.05); the serum calcium in treatment group was significantly higher than that in control group ( P<0.05), while the blood phosphorus and iPTH were significantly lower than those in control group ( P<0.05). The KDTA scores in the two groups were significantly increased ( P<0.05), while the VAS scores were significantly decreased ( P<0.05); the KDTA score in treatment group was significantly higher than that in control group ( P<0.05), while the VAS score was significantly lower than that in control group ( P<0.05). There was no significant difference in adverse reactions between the two groups ( P>0.05). Conclusions:The treatment effect of salmon calcitonin combined with vitamin D3 on chronic renal insufficiency secondary hyperthyroidism is obvious, and the clinical symptoms such as bone pain are improved obviously. It is believed that salmon calcitonin is related to the regulation of calcium, phosphorus and bone metabolism.